ZymoGenetics rated at buy by Merrill

Merrill Lynch analyst Hari Sambasivam rated ZymoGenetics Inc. at a buy after Omrix Biopharmaceuticals disclosed data for its plasma derived human thrombin compared to King Pharmaceuticals' bovine thrombin. Plasma derived human thrombin was comparable to bovine thrombin in relation to the primary and secondary efficacy endpoints, with more serious adverse events with human thrombin (17%) compared to bovine thrombin (11%). No immunogenicity data were released. Key differentiators for the various thrombins include safety, antibody formation and implications for bleeding complications, with ZymoGenetics' recombinant thrombin likely to emerge as the dominant player, according to the analyst. Shares of the Seattle-based pharmaceutical company were up 35 cents, or 1.91%, at $18.64. (Nasdaq: ZGEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.